Source: Clinical Trials Arena

ImmunogenX: ImmunogenX starts enrolment in Phase IIb celiac disease study

Biotherapeutics company ImmunogenX has commenced patient enrolment in a Phase IIb clinical trial of Latiglutenase (IMGX003) for the treatment of...Read More...The post ImmunogenX starts enrolment in Phase IIb celiac disease study appeared first on Clinical Trials Arena.

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

Co-Founder & CEO

Jack A. Syage

CEO Approval Rating

85/100

ImmunogenX focused on the diagnosis and treatment of autoimmune and gastrointestinal diseases.